Observing local relapse in patients with high-grade osteosarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter observational study aims to analyze cases of local relapse in patients diagnosed with high-grade osteosarcoma. It includes both retrospective data from January 1980 and prospective data from new cases at participating sites. The study will focus on patients who experienced local relapse as their first recurrence event after treatment, including those with synchronous lung metastases. The goal is to gather comprehensive data to better understand the patterns and outcomes of local relapse in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who experienced LR as first event of recurrence after treatment for localized high-grade osteosarcoma of bone, including cases with synchronous lung metastases
* Adequate patient compliance to follow-up visits
* Written informed consent prior to any study-specific analysis and/or data collection
* No age limits

Exclusion Criteria:

* Cases of LR demonstrated after \> 3 months after metastatic disease
* Impossibility to ensure adequate compliance

Where it's running

• IRCCS Istituto Ortopedico Rizzoli
  Bologna, Bo, Italy Recruiting
• Azienda Ospedaliero-Universitaria Pisana
  Pisa, Pi, Italy Recruiting

Study contacts

• Study coordinator: Emanuela Palmerini, MD
• Email: emanuela.palmerini@ior.it
• Phone: 051/6366

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fight Osteosarcoma with a European, evolving research platform from diagnosis to relapse

  A European platform trial in pediatric and young adult high-grade osteosarcoma will test Cabometyx as one treatment option while collecting tumor and blood samples to guide future strategies.

  Recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Aarhus and 76 other locations · NCT07871864

• Immunotherapy plus standard treatment for high-risk osteosarcoma in kids and young adults

  This study tests mifamurtide added to standard chemotherapy versus standard treatment with sorafenib to see if the combination helps patients with high-risk osteosarcoma.

  Recruiting Phase 2 Institute of Mother and Child, Warsaw, Poland · Warsaw, Mazovian · NCT07787429

• 68Ga-B7-H3 Nanobody PET Imaging in Osteosarcoma

  This study tests a new gallium-68 labeled B7-H3 nanobody to see if it can image osteosarcoma tumors more clearly.

  Recruiting Early Phase 1 Peking University First Hospital · Beijing, Beijing Municipality · NCT07774533

• Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma

  This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.

  Recruiting at 2 sites Phase 1/2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 3 other locations · NCT07725380

• Neoantigen Vaccine SarVac With Tumor-Specific Lymphocytes Plus PD-1 Blocker for Advanced Sarcoma

  This trial tests a personalized cancer vaccine called SarVac, given with a PD-1 blocker, and possibly tumor-specific lymphocytes, to see if it is safe and can help people with advanced soft tissue or bone sarcoma.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07648069

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.